TY - JOUR AU - Crombie, J. L. PY - 2020 DA - 2020// TI - Diffuse large B-cell lymphoma and high-grade b-cell lymphoma: genetic classification and its implications for prognosis and treatment JO - Surg Oncol Clin N Am VL - 29 UR - https://doi.org/10.1016/j.soc.2019.08.009 DO - 10.1016/j.soc.2019.08.009 ID - Crombie2020 ER - TY - JOUR AU - Nowakowski, G. S. PY - 2016 DA - 2016// TI - Beyond RCHOP: a blueprint for diffuse large B cell lymphoma research JO - J Natl Cancer Inst VL - 108 UR - https://doi.org/10.1093/jnci/djw257 DO - 10.1093/jnci/djw257 ID - Nowakowski2016 ER - TY - JOUR AU - Lenz, G. PY - 2013 DA - 2013// TI - Novel therapeutic targets in diffuse large B-cell lymphoma JO - EJC Suppl VL - 11 UR - https://doi.org/10.1016/j.ejcsup.2013.07.041 DO - 10.1016/j.ejcsup.2013.07.041 ID - Lenz2013 ER - TY - JOUR AU - Tilly, H. PY - 2015 DA - 2015// TI - Diffuse large B-cell lymphoma (DLBCL): ESMO clinical practice guidelines for diagnosis, treatment and follow-up JO - Ann Oncol VL - 26 UR - https://doi.org/10.1093/annonc/mdv304 DO - 10.1093/annonc/mdv304 ID - Tilly2015 ER - TY - JOUR AU - Kim, S. W. PY - 2020 DA - 2020// TI - High-dose therapy and autologous stem cell transplantation for relapsed or high-risk diffuse large B-cell lymphoma: a nationwide survey JO - Int J Hematol VL - 111 UR - https://doi.org/10.1007/s12185-019-02772-1 DO - 10.1007/s12185-019-02772-1 ID - Kim2020 ER - TY - JOUR AU - Eyre, T. A. PY - 2019 DA - 2019// TI - A phase II study to assess the safety and efficacy of the dual mTORC1/2 inhibitor vistusertib in relapsed, refractory DLBCL JO - Hematol Oncol VL - 37 UR - https://doi.org/10.1002/hon.2662 DO - 10.1002/hon.2662 ID - Eyre2019 ER - TY - JOUR AU - Buchner, M. PY - 2014 DA - 2014// TI - Targeting the B-cell receptor signaling pathway in B lymphoid malignancies JO - Curr Opin Hematol VL - 21 UR - https://doi.org/10.1097/MOH.0000000000000048 DO - 10.1097/MOH.0000000000000048 ID - Buchner2014 ER - TY - JOUR AU - Maxwell, S. A. PY - 2013 DA - 2013// TI - Non-Hodgkin’s B-cell lymphoma: advances in molecular strategies targeting drug resistance JO - Exp Biol Med (Maywood) VL - 238 UR - https://doi.org/10.1177/1535370213498985 DO - 10.1177/1535370213498985 ID - Maxwell2013 ER - TY - JOUR AU - Smith, S. M. PY - 2015 DA - 2015// TI - New drugs for the treatment of non-Hodgkin lymphomas JO - Chin Clin Oncol VL - 4 ID - Smith2015 ER - TY - JOUR AU - Rodgers, T. D. PY - 2018 DA - 2018// TI - Targeting the B-cell receptor pathway: a review of current and future therapies for non-Hodgkin’s lymphoma JO - Expert Opin Emerg Drugs VL - 23 UR - https://doi.org/10.1080/14728214.2018.1479396 DO - 10.1080/14728214.2018.1479396 ID - Rodgers2018 ER - TY - JOUR AU - Caldwell, R. PY - 2018 DA - 2018// TI - Discovery of a novel series of pyridine and pyrimidine carboxamides as potent and selective covalent inhibitors of Btk JO - Bioorg Med Chem Lett VL - 28 UR - https://doi.org/10.1016/j.bmcl.2018.09.033 DO - 10.1016/j.bmcl.2018.09.033 ID - Caldwell2018 ER - TY - JOUR AU - Honigberg, L. A. PY - 2010 DA - 2010// TI - The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy JO - Proc Natl Acad Sci USA VL - 107 UR - https://doi.org/10.1073/pnas.1004594107 DO - 10.1073/pnas.1004594107 ID - Honigberg2010 ER - TY - JOUR AU - Xia, B. PY - 2015 DA - 2015// TI - Targeting Bruton’s tyrosine kinase signaling as an emerging therapeutic agent of B-cell malignancies (Review) JO - Oncol Lett VL - 10 UR - https://doi.org/10.3892/ol.2015.3802 DO - 10.3892/ol.2015.3802 ID - Xia2015 ER - TY - JOUR AU - Goede, V. PY - 2014 DA - 2014// TI - Chemoimmunotherapy for chronic lymphocytic leukemia REPLY JO - N Engl J Med VL - 370 UR - https://doi.org/10.1056/NEJMc1404855 DO - 10.1056/NEJMc1404855 ID - Goede2014 ER - TY - JOUR AU - Burger, J. A. PY - 2014 DA - 2014// TI - Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study JO - Lancet Oncol VL - 15 UR - https://doi.org/10.1016/S1470-2045(14)70335-3 DO - 10.1016/S1470-2045(14)70335-3 ID - Burger2014 ER - TY - JOUR AU - Caimi, P. F. PY - 2016 DA - 2016// TI - Clinical approach to diffuse large B cell lymphoma JO - Blood Rev VL - 30 UR - https://doi.org/10.1016/j.blre.2016.06.003 DO - 10.1016/j.blre.2016.06.003 ID - Caimi2016 ER - TY - JOUR AU - Davis, R. E. PY - 2010 DA - 2010// TI - Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma JO - Nature VL - 463 UR - https://doi.org/10.1038/nature08638 DO - 10.1038/nature08638 ID - Davis2010 ER - TY - JOUR AU - O'Donnell, M. A. PY - 2010 DA - 2010// TI - Chronicles of a death foretold: dual sequential cell death checkpoints in TNF signaling JO - Cell Cycle VL - 9 UR - https://doi.org/10.4161/cc.9.6.10982 DO - 10.4161/cc.9.6.10982 ID - O'Donnell2010 ER - TY - JOUR AU - Yu, L. PY - 2008 DA - 2008// TI - Proteasome-dependent autoregulation of Bruton tyrosine kinase (Btk) promoter via NF-kappaB JO - Blood VL - 111 UR - https://doi.org/10.1182/blood-2007-10-121137 DO - 10.1182/blood-2007-10-121137 ID - Yu2008 ER - TY - JOUR AU - Massoumi, R. PY - 2010 DA - 2010// TI - Ubiquitin chain cleavage: CYLD at work JO - Trends Biochem Sci VL - 35 UR - https://doi.org/10.1016/j.tibs.2010.02.007 DO - 10.1016/j.tibs.2010.02.007 ID - Massoumi2010 ER - TY - JOUR AU - Bignell, G. R. AU - William, W. PY - 2000 DA - 2000// TI - Identification of the familial cylindromatosis tumour-suppressor gene JO - Nat Genet VL - 25 UR - https://doi.org/10.1038/76006 DO - 10.1038/76006 ID - Bignell2000 ER - TY - JOUR AU - Miliani de Marval, P. PY - 2011 DA - 2011// TI - CYLD inhibits tumorigenesis and metastasis by blocking JNK/AP1 signaling at multiple levels JO - Cancer Prev Res (Phila) VL - 4 UR - https://doi.org/10.1158/1940-6207.CAPR-10-0360 DO - 10.1158/1940-6207.CAPR-10-0360 ID - Miliani de Marval2011 ER - TY - JOUR AU - Oshiumi, H. PY - 2012 DA - 2012// TI - Ubiquitin-mediated modulation of the cytoplasmic viral RNA sensor RIG-I JO - J Biochem VL - 151 UR - https://doi.org/10.1093/jb/mvr111 DO - 10.1093/jb/mvr111 ID - Oshiumi2012 ER - TY - JOUR AU - Xu, X. PY - 2020 DA - 2020// TI - Reversal of CYLD phosphorylation as a novel therapeutic approach for adult T-cell leukemia/lymphoma (ATLL) JO - Cell Death Dis VL - 11 UR - https://doi.org/10.1038/s41419-020-2294-6 DO - 10.1038/s41419-020-2294-6 ID - Xu2020 ER - TY - JOUR AU - Saleh, L. M. PY - 2017 DA - 2017// TI - Ibrutinib downregulates a subset of miRNA leading to upregulation of tumor suppressors and inhibition of cell proliferation in chronic lymphocytic leukemia JO - Leukemia VL - 31 UR - https://doi.org/10.1038/leu.2016.181 DO - 10.1038/leu.2016.181 ID - Saleh2017 ER - TY - JOUR AU - Swerdlow, S. H. PY - 2016 DA - 2016// TI - The 2016 revision of the World Health Organization classification of lymphoid neoplasms JO - Blood VL - 127 UR - https://doi.org/10.1182/blood-2016-01-643569 DO - 10.1182/blood-2016-01-643569 ID - Swerdlow2016 ER - TY - JOUR AU - Vrana, M. PY - 2016 DA - 2016// TI - An optimized method for protein extraction from OCT-embedded human kidney tissue for protein quantification by LC-MS/MS proteomics JO - Drug Metab Dispos VL - 44 UR - https://doi.org/10.1124/dmd.116.071522 DO - 10.1124/dmd.116.071522 ID - Vrana2016 ER - TY - JOUR AU - He, K. L. PY - 2003 DA - 2003// TI - Essential role for IKKgamma/NEMO in TCR-induced IL-2 expression in Jurkat T cells JO - Eur J Immunol VL - 33 UR - https://doi.org/10.1002/eji.200323650 DO - 10.1002/eji.200323650 ID - He2003 ER - TY - JOUR AU - Czuczman, M. S. PY - 2008 DA - 2008// TI - Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels JO - Clin Cancer Res VL - 14 UR - https://doi.org/10.1158/1078-0432.CCR-07-1254 DO - 10.1158/1078-0432.CCR-07-1254 ID - Czuczman2008 ER - TY - JOUR AU - Ezell, S. A. PY - 2014 DA - 2014// TI - Synergistic induction of apoptosis by combination of BTK and dual mTORC1/2 inhibitors in diffuse large B cell lymphoma JO - Oncotarget VL - 5 UR - https://doi.org/10.18632/oncotarget.2071 DO - 10.18632/oncotarget.2071 ID - Ezell2014 ER - TY - JOUR AU - Naito, S. PY - 1986 DA - 1986// TI - Growth and metastasis of tumor cells isolated from a human renal cell carcinoma implanted into different organs of nude mice JO - Can Res VL - 46 ID - Naito1986 ER - TY - JOUR AU - He, K. L. PY - 2002 DA - 2002// TI - A20 inhibits tumor necrosis factor (TNF) alpha-induced apoptosis by disrupting recruitment of TRADD and RIP to the TNF receptor 1 complex in Jurkat T cells JO - Mol Cell Biol VL - 22 UR - https://doi.org/10.1128/MCB.22.17.6034-6045.2002 DO - 10.1128/MCB.22.17.6034-6045.2002 ID - He2002 ER - TY - JOUR AU - Legarda, D. PY - 2016 DA - 2016// TI - CYLD proteolysis protects macrophages from TNF-mediated auto-necroptosis induced by LPS and licensed by type I IFN JO - Cell Rep VL - 15 UR - https://doi.org/10.1016/j.celrep.2016.05.032 DO - 10.1016/j.celrep.2016.05.032 ID - Legarda2016 ER - TY - JOUR AU - Kalantary-Charvadeh, A. PY - 2019 DA - 2019// TI - Micheliolide protects against doxorubicin-induced cardiotoxicity in mice by regulating PI3K/Akt/NFκB signaling pathway JO - Cardiovasc Toxicol VL - 19 UR - https://doi.org/10.1007/s12012-019-09511-2 DO - 10.1007/s12012-019-09511-2 ID - Kalantary-Charvadeh2019 ER - TY - STD TI - Kielkopf CL, et al. Bradford assay for determining protein concentration. Cold Spring Harb Protoc. 2020;2020(4). https://doi.org/10.1101/pdb.prot102269. ID - ref35 ER - TY - JOUR AU - Hendriks, R. W. PY - 2014 DA - 2014// TI - Targeting Bruton’s tyrosine kinase in B cell malignancies JO - Nat Rev Cancer VL - 14 UR - https://doi.org/10.1038/nrc3702 DO - 10.1038/nrc3702 ID - Hendriks2014 ER - TY - JOUR AU - Buggy, J. J. PY - 2012 DA - 2012// TI - Bruton tyrosine kinase (BTK) and its role in B-cell malignancy JO - Int Rev Immunol VL - 31 UR - https://doi.org/10.3109/08830185.2012.664797 DO - 10.3109/08830185.2012.664797 ID - Buggy2012 ER - TY - JOUR AU - Advani, R. H. PY - 2013 DA - 2013// TI - Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies JO - J Clin Oncol VL - 31 UR - https://doi.org/10.1200/JCO.2012.42.7906 DO - 10.1200/JCO.2012.42.7906 ID - Advani2013 ER - TY - JOUR AU - Jiahui Lv, J. W. PY - 2018 DA - 2018// TI - Development of Bruton’s tyrosine kinase inhibitors for rheumatoid arthritis JO - Curr Med Chem VL - 25 ID - Jiahui Lv2018 ER - TY - JOUR AU - Ran, F. PY - 2020 DA - 2020// TI - Design and synthesis of novel 1-substituted 3-(6-phenoxypyridin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine analogs as selective BTK inhibitors for the treatment of mantle cell lymphoma JO - Bioorg Chem VL - 94 UR - https://doi.org/10.1016/j.bioorg.2019.103367 DO - 10.1016/j.bioorg.2019.103367 ID - Ran2020 ER - TY - JOUR AU - Chu, Y. PY - 2019 DA - 2019// TI - Ibrutinib significantly inhibited Bruton’s tyrosine kinase (BTK) phosphorylation, in-vitro proliferation and enhanced overall survival in a preclinical Burkitt lymphoma (BL) model JO - Oncoimmunology VL - 8 UR - https://doi.org/10.1080/2162402X.2018.1512455 DO - 10.1080/2162402X.2018.1512455 ID - Chu2019 ER - TY - JOUR AU - Davis, R. E. PY - 2001 DA - 2001// TI - Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells JO - J Exp Med VL - 194 UR - https://doi.org/10.1084/jem.194.12.1861 DO - 10.1084/jem.194.12.1861 ID - Davis2001 ER - TY - JOUR AU - Jost, P. J. PY - 2007 DA - 2007// TI - Aberrant NF-kappaB signaling in lymphoma: mechanisms, consequences, and therapeutic implications JO - Blood VL - 109 UR - https://doi.org/10.1182/blood-2006-07-025809 DO - 10.1182/blood-2006-07-025809 ID - Jost2007 ER - TY - JOUR AU - Danilenko, M. PY - 2018 DA - 2018// TI - Targeting tropomyosin receptor kinase in cutaneous CYLD defective tumors with pegcantratinib: the TRAC randomized clinical trial JO - JAMA Dermatol VL - 154 UR - https://doi.org/10.1001/jamadermatol.2018.1610 DO - 10.1001/jamadermatol.2018.1610 ID - Danilenko2018 ER - TY - JOUR AU - Deng, L. L. PY - 2012 DA - 2012// TI - Over-expressing CYLD augments antitumor activity of TRAIL by inhibiting the NF-kappaB survival signaling in lung cancer cells JO - Neoplasma VL - 59 UR - https://doi.org/10.4149/neo_2012_003 DO - 10.4149/neo_2012_003 ID - Deng2012 ER - TY - JOUR AU - Song, H. PY - 2018 DA - 2018// TI - MicroRNA-301b promotes cell proliferation and apoptosis resistance in triple-negative breast cancer by targeting CYLD JO - BMB Rep VL - 51 UR - https://doi.org/10.5483/BMBRep.2018.51.11.168 DO - 10.5483/BMBRep.2018.51.11.168 ID - Song2018 ER - TY - JOUR AU - Hayashi, M. PY - 2014 DA - 2014// TI - Clinical significance of CYLD downregulation in breast cancer JO - Breast Cancer Res Treat VL - 143 UR - https://doi.org/10.1007/s10549-013-2824-3 DO - 10.1007/s10549-013-2824-3 ID - Hayashi2014 ER - TY - JOUR AU - Yong, W. PY - 2018 DA - 2018// TI - Expression and correlation of tumor suppressor Sema3F, CYLD and mir-454 in patients with rectal cancer JO - Dev Modern Gen Surg China VL - 21 ID - Yong2018 ER - TY - JOUR AU - Wu, W. PY - 2014 DA - 2014// TI - Clinical significance of down-regulated cylindromatosis gene in chronic lymphocytic leukemia JO - Leuk Lymphoma VL - 55 UR - https://doi.org/10.3109/10428194.2013.809077 DO - 10.3109/10428194.2013.809077 ID - Wu2014 ER - TY - JOUR AU - Jenner, M. W. PY - 2007 DA - 2007// TI - Gene mapping and expression analysis of 16q loss of heterozygosity identifies WWOX and CYLD as being important in determining clinical outcome in multiple myeloma JO - Blood VL - 110 UR - https://doi.org/10.1182/blood-2007-02-075069 DO - 10.1182/blood-2007-02-075069 ID - Jenner2007 ER - TY - JOUR AU - Schmidt, A. PY - 2010 DA - 2010// TI - Rare occurrence of biallelic CYLD gene mutations in classical Hodgkin lymphoma JO - Genes Chromosomes Cancer VL - 49 ID - Schmidt2010 ER - TY - JOUR AU - Andel, H. PY - 2017 DA - 2017// TI - Loss of CYLD expression unleashes Wnt signaling in multiple myeloma and is associated with aggressive disease JO - Oncogene VL - 36 UR - https://doi.org/10.1038/onc.2016.368 DO - 10.1038/onc.2016.368 ID - Andel2017 ER - TY - JOUR AU - Arora, M. PY - 2015 DA - 2015// TI - Functional nature of a novel mutant CYLD observed in pediatric lymphoblastic B-cell leukemia JO - Pediatr Blood Cancer VL - 62 UR - https://doi.org/10.1002/pbc.25387 DO - 10.1002/pbc.25387 ID - Arora2015 ER - TY - JOUR AU - Arora, M. PY - 2015 DA - 2015// TI - Cellular proteolytic modification of tumor-suppressor CYLD is critical for the initiation of human T-cell acute lymphoblastic leukemia JO - Blood Cells Mol Dis VL - 54 UR - https://doi.org/10.1016/j.bcmd.2014.07.008 DO - 10.1016/j.bcmd.2014.07.008 ID - Arora2015 ER - TY - JOUR AU - Smith, M. R. PY - 2003 DA - 2003// TI - Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance JO - Oncogene VL - 22 UR - https://doi.org/10.1038/sj.onc.1206939 DO - 10.1038/sj.onc.1206939 ID - Smith2003 ER - TY - JOUR AU - Torka, P. PY - 2019 DA - 2019// TI - Mechanisms of resistance to monoclonal antibodies (mAbs) in lymphoid malignancies JO - Curr Hematol Malig Rep VL - 14 UR - https://doi.org/10.1007/s11899-019-00542-8 DO - 10.1007/s11899-019-00542-8 ID - Torka2019 ER - TY - JOUR AU - Reiff, S. D. PY - 2018 DA - 2018// TI - The BTK inhibitor ARQ 531 targets ibrutinib-resistant CLL and richter transformation JO - Cancer Discov VL - 8 UR - https://doi.org/10.1158/2159-8290.CD-17-1409 DO - 10.1158/2159-8290.CD-17-1409 ID - Reiff2018 ER - TY - JOUR AU - Davids, M. S. PY - 2017 DA - 2017// TI - Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma JO - J Clin Oncol VL - 35 UR - https://doi.org/10.1200/JCO.2016.70.4320 DO - 10.1200/JCO.2016.70.4320 ID - Davids2017 ER - TY - JOUR AU - Hartert, K. T. PY - 2020 DA - 2020// TI - Targeting of inflammatory pathways with R2CHOP in high-risk DLBCL JO - Leukemia UR - https://doi.org/10.1038/s41375-020-0766-4 DO - 10.1038/s41375-020-0766-4 ID - Hartert2020 ER - TY - JOUR AU - Kuhnl, A. PY - 2020 DA - 2020// TI - R-GEM-Lenalidomide versus R-GEM-P as second-line treatment of diffuse large B-cell lymphoma: results of the UK NRCI phase II randomised LEGEND trial JO - Ann Hematol VL - 99 UR - https://doi.org/10.1007/s00277-019-03842-4 DO - 10.1007/s00277-019-03842-4 ID - Kuhnl2020 ER - TY - JOUR AU - Ferreri, A. J. M. PY - 2020 DA - 2020// TI - Long-lasting efficacy and safety of lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for or failed autologous transplantation JO - Hematol Oncol UR - https://doi.org/10.1002/hon.2742 DO - 10.1002/hon.2742 ID - Ferreri2020 ER - TY - JOUR AU - Lork, M. PY - 2018 DA - 2018// TI - Importance of validating antibodies and small compound inhibitors using genetic knockout studies-T cell receptor-induced CYLD phosphorylation by IKKepsilon/TBK1 as a case study JO - Front Cell Dev Biol VL - 6 UR - https://doi.org/10.3389/fcell.2018.00040 DO - 10.3389/fcell.2018.00040 ID - Lork2018 ER -